Marco Pravetoni, PhD

The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.

Education

PhD in Pharmacology, University of Minnesota, 2008

Department Affiliations

Scholarly Expertise

  • Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling

Recent Publications

Immunotherapeutic Strategies for Treating Opioid Use Disorder and Overdose.
(2023 Jan 25)
Expert Opin Investig Drugs
Luba R, Martinez S, Jones J, Pravetoni M, Comer SD

Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding.
(2023 Jan 5)
Structure 31(1): 20-32.e5
Rodarte JV, Baehr C, Hicks D, Liban TL, Weidle C, Rupert PB, Jahan R, Wall A, McGuire AT, Strong RK, Runyon S, Pravetoni M, Pancera M

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.
(2023 Jan 1)
JAMA Psychiatry 80(1): 84-92
Kiluk BD, Kleykamp BA, Comer SD, Griffiths RR, Huhn AS, Johnson MW, Kampman KM, Pravetoni M, Preston KL, Vandrey R, Bergeria CL, Bogenschutz MP, Brown RT, Dunn KE, Dworkin RH, Finan PH, Hendricks PS, Houtsmuller EJ, Kosten TR, Lee DC, Levin FR, McRae-Clark A, Raison CL, Rasmussen K, Turk DC, Weiss RD, Strain EC

Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development.
(2022 Nov 30)
Hum Vaccin Immunother 18(6): 2122507
Hicks D, Baehr C, Silva-Ortiz P, Khaimraj A, Luengas D, Hamid FA, Pravetoni M

Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in Rats.
(2022 May 17)
ACS Omega 7(19): 16584-16592
Baehr C, Robinson C, Kassick A, Jahan R, Gradinati V, Averick SE, Runyon SP, Pravetoni M

Show complete publication list »
Edit Profile